An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

ÇİÇİN, İRFAN; Oukkal, Mohammed; Mahfouf, Hassen; Mezlini, Amel; Larbaoui, Blaha; Ben Ahmed, Slim; Errihani, Hassan; Alsaleh, Khalid; Belbaraka, Rhizlane; Yumuk, Perran; Goktas, Burçe; ÖZGÜROĞLU, MUSTAFA

doi:10.4274/ejbh.galenos.2021.2021-9-9

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

ÇİÇİN İ., Oukkal M., Mahfouf H., Mezlini A., Larbaoui B., Ben Ahmed S., ...More

EUROPEAN JOURNAL OF BREAST HEALTH, vol.18, no.1, pp.63-73, 2022 (Journal Indexed in ESCI)

Publication Type: Article / Article
Volume: 18 Issue: 1
Publication Date: 2022
Doi Number: 10.4274/ejbh.galenos.2021.2021-9-9
Title of Journal : EUROPEAN JOURNAL OF BREAST HEALTH
Page Numbers: pp.63-73
Keywords: subcutaneous, trastuzumab, breast cancer, HER2, patient satisfaction, ADJUVANT CHEMOTHERAPY, FINAL ANALYSIS, SAFETY, TOLERABILITY, EXPERIENCE

Abstract

Objective: This study was designed to investigate treatment satisfaction in patients and Health Care Professionals (HCP) and to evaluate the safety and tolerability of subcutaneous (SC) trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC).